XWXiaofeng Wang

Xiaofeng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaofeng Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Xu

    Department of Orthopaedics, Zhejiang Chinese Medical University Affiliated Wenzhou; Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang, China

    2 shared publications
  • Ou Chen

    Department of Orthopaedics, Zhejiang Chinese Medical University Affiliated Wenzhou; Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang, China

    2 shared publications
  • Chengliang Wu

    Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

    1 shared publication
  • Duan Jin Shuai

    Affiliation Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Zhejiang Chinese Medical University, Zhejiang University of Traditional Chinese Medicine, Wengzhou, Zhejiang, Peoples R China

    1 shared publication
  • Gong YouJia

    Affiliation The Third Clinical College of Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang, Peoples R China

    1 shared publication
  • Guo KeChun

    Affiliation Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Zhejiang Chinese Medical University, Zhejiang University of Traditional Chinese Medicine, Wengzhou, Zhejiang, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    Assessing the efficacy and safety of different nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis: A systematic review and network meta-analysis based on RCT trials

    by Pan JiaoYi, Sun YongQi, Guo KeChun, Li XingYu, Liu ZeZhong, Duan Jin Shuai, Gong YouJia, Xu Bing, Wang XiaoFeng

    Introduction: Osteoarthritis (OA) as a degenerative disease, has seen a continuous rise in incidence and prevalence globally since 1990, imposing a significant disease burden. NSAIDs (Nonsteroidal anti-inflammatory drugs) as symptomatic medications for OA treatment, hold an indispensable position in clinical practice. Objective: To evaluate the efficacy and safety of different NSAIDs in the treatment of OA through Bayesian Network Meta-Analysis (NMA). Methods: Randomized controlled trials (RCTs) on NSAIDs for OA treatment were retrieved from PubMed, Web of Science, Embase, and the Cochrane Library databases. The search timeframe was from the inception of each database up to June 1, 2024. Outcome indicators for NMA were all conducted using a random-effects model. MetaInsight and Stata 14.0 software were used in R for calculations and plotting of NMA. Measurement data were represented by mean difference (MD), and count data by odds ratio (OR); a 95% confidence interval (CI) was also calculated for each effect size. Results: This study included 31 studies, involving 68,539 patients with knee osteoarthritis (KOA) and 16 interventions. NMA results showed that compared to the placebo, Tiaprofenic reduced the VAS score (MD = -0.16, 95% CI: (-0.46 to 0.14), P > 0.05), albeit without significant difference; meanwhile, Diclofenac reduced the total WOMAC score in KOA patients (MD = -0.41, 95% CI: -1.05 to 0.24, P > 0.05). Compared to the placebo, Etoricoxib was the best medication for improving the WOMAC pain subscale score (MD = -0.44; 95% CI: -0.61 to -0.26); Naproxen significantly improved the WOMAC Function score in KOA patients after administration (MD = -0.43; 95% CI: -0.82 to -0.04); Diclofenac intervention significantly reduced the WOMAC Stiffness score in KOA patients (MD = -0.40; 95% CI: -0.67 to -0.13). In terms of adverse event rates, compared to the placebo, the use of Etoricoxib significantly increased the incidence of cardiovascular adverse events (OR = 0.56, 95% CI: 0.32–0.99); Ketoprofen had fewer gastrointestinal adverse events during the medication process (OR = 0.09, 95% CI: 0.04–0.20); Licofelone had a lower rate of other adverse events during the medication process (OR = 0.80, 95% CI: 0.45–1.40, P > 0.05). Therefore, the results indicate that Etoricoxib, Tiaprofenic, Naproxen, Diclofenac, and Ketoprofen have better clinical efficacy and safety. Conclusion: Compared to other NSAIDs, Etoricoxib, Tiaprofenic, Naproxen, and Diclofenac play a more effective role in improving clinical symptoms of OA; in terms of reducing the incidence of adverse events, Ketoprofen has a lower chance of adverse events. However, the possibility of these results still needs further clinical and basic research for verification.


  • Open Access

    Single-cell profiling uncovers synovial fibroblast subpopulations associated with chondrocyte injury in osteoarthritis

    by Zezhong Liu, Yongqi Sun, Jiaoyi Pan, Kechun Guo, Zhi Tang, Xiaofeng Wang

    Background: Chondrocytes and synovial cells participate in the pathogenesis of osteoarthritis (OA). Nonetheless, the interactions and correlations between OA synovial cells and chondrocytes remain unclear. This study aims to elucidate the interactions and correlations between OA synovial cells and chondrocytes, so as to deepen understanding of OA pathogenesis.Methods: Single-cell sequencing analysis was employed to analyze clusters of synovial and chondrocyte cells within the OA dataset. Through cell interaction analysis, the potential interactions between these two cell types were further explored. Differential gene expression analysis was used to examine the differences among synovial-related cell clusters.Results: The study identified specific characteristics of synovial fibroblasts through single-cell sequencing analysis. Subsequent cell interaction analysis revealed interactions and correlations between synovial fibroblast clusters and cell clusters in both damaged and non-damaged cartilages. CILP+ fibroblasts showed significant interactions with non-damaged chondrocytes, while POSTN+ fibroblasts exhibited significant interactions with damaged chondrocytes. Furthermore, differential gene expression analysis revealed that genes such as PRELP, CLU, COMP, TNFRSF12A, INHBA, CILP, and SERPINE2, were significantly upregulated in CILP+ fibroblasts. These genes are involved in promoting cell proliferation, inhibiting inflammatory pathways, and stabilizing cell structure, thereby exerting reparative and protective effects on chondrocytes. In contrast, COL6A3, COL6A1, COL1A2, COL1A1, COL3A1, TGF-β1, MMP2, AEBP1, SPARC, FNDC1, and POSTN were upregulated in POSTN+ fibroblasts. These genes may contribute to chondrocyte damage and further degeneration by promoting chondrocyte catabolism, driving inflammation, activating inflammatory pathways, and facilitating chondrocyte apoptosis and destruction.Conclusion: Our study elucidated the interactions and correlations between OA synovial cells and chondrocytes. CILP+ synovial fibroblasts may exert reparative and protective effects on chondrocytes of patients with OA by promoting cell proliferation, inhibiting inflammation, and stabilizing cellular structures, thereby potentially mitigating the progression of cartilage lesions in affected patients. In contrast, POSTN+ synovial fibroblasts may exacerbate chondrocyte deterioration in patients with OA by enhancing degradation, inflammation, and apoptosis, thereby exacerbating cartilage lesions. Investigating the underlying molecular mechanisms between OA synovial cells and chondrocytes refines the understanding of OA pathogenesis and provides valuable insights for the clinical diagnosis and treatment of OA.


  • Open Access

    Flavonoid compound icariin enhances BMP-2 induced differentiation and signalling by targeting to connective tissue growth factor (CTGF) in SAMP6 osteoblasts

    by Bing Xu, Xueqiang Wang, Chengliang Wu, Lihe Zhu, Ou Chen, Xiaofeng Wang

    Icariin, a major active flavonoid glucoside, is widely used for the treatment of bone injury and rebuilding in the clinic because of its roles in suppressing osteoblastogenesis and promoting osteogenesis. The senescence-accelerated mouse SAMP6 was accepted as a useful murine model to reveal the mechanism of senile osteoporosis and the therapeutic mechanism of drug activity. However, little is known about the characteristics of SAMP6 osteoblasts and the associated regulatory roles of icariin. We isolated and cultured osteoblasts from SAMP6 or SAMR1 mice and compared their proliferation, migration, and differentiation by performing the CCK-8 assay, cell counting assay, EdU staining, cell cycle analysis, ALP staining and activity measurement, Alizarin red staining, and RT-qPCR analysis to measure the levels of osteoblast markers, including RUNX2, Colla1 and Oc. To assess the effects of icariin on BMP-2-induced osteoblast differentiation, after BMP-2 treatment, osteoblast markers were analyzed by RT-qPCR and semi-quantitative Western blotting. The effects of icariin on connective tissue growth factor (CTGF) were measured by RT-qPCR. shRNA targeting CTGF mRNA was employed to knockdown its expression level in osteoblasts. The SAMP6 osteoblasts presented decreased the development and differentiation activity compared with SAMR1 osteoblasts, indicating that they are the potential mechanisms underlying age-associated disease. Moreover, SAMP6 osteoblasts presented upregulated CTGF compared with SAMR1 osteoblasts. Icariin enhanced BMP-2-induced osteoblast differentiation by downregulating CTGF expression, which tightly regulates osteoblast differentiation. By downregulating CTGF, icariin treatment upregulated phosphate-Smad1/5/8, indicating its activating effects on the BMP signaling pathway. These results suggest that decreased osteoblast development and function potentially contributes to age-associated disease. Icariin exerts enhancing effects on BMP-2-mediated osteoblast development via downregulating CTGF.


  • Antenatal taurine supplementation improves cerebral neurogenesis in fetal rats with intrauterine growth restriction through the PKA-CREB signal pathway

    by Jing Liu, Ying Liu, Xiao-Feng Wang, Hui Chen, Na Yang

    This study seeks to explore whether antenatal supplement of taurine may improve the brain development of fetal rats with intrauterine growth restriction (IUGR) via the protein kinase A-cyclic adenosine monophosphate (cAMP) response element protein (PKA-CREB) pathway. Fifteen pregnant rats were randomly divided into control group, IUGR model, and IUGR with antenatal taurine supplement group. Brain tissues were obtained immediately after rats were born. PKA-CREB signal pathway activity and glial cell line-derived neurotrophic factor (GDNF) mRNA and protein levels were measured by reverse transcription polymerase chain reaction and immunohistochemistry stains, whereas immunoreactive cells of neuron-specific enolase (NSE) and proliferating cell nuclear antigen (PCNA) were detected by immunohistochemistry stains. The results showed that: (1) In the IUGR group, a greater number of PCNA and NSE immunoreactive cells were found in brain tissues compared with controls, and prenatal taurine supplementation led to a further increase. (2) Expression of PKA, CREB, and GDNF were increased in mRNA and protein levels due to taurine supplementation. Antenatal taurine supplementation shows effects of promotion of cell proliferation and activation of neurotrophic factors on fetal rat brain in a model of IUGR by activating the PKA-CREB signal pathway, increasing expression of neurotrophic factors, and promoting cell proliferation to counteract neuron loss caused by IUGR.